Supraventricular arrhythmias. Atrial fibrillation and flutter
Conditions
Interventions
Intervention group: Taking empagliflozin tablets from Abidi Company, 10 mg/day in the morning, regardless of food for three months (30 patients).
Sponsors
Bagheiat-allah University of Medical Sciences
Mashhad University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Age more than 18 years Diagnosis of heart failure based on echocardiography Having an ICD for more than 3 months before starting participation in the study Obtaining the patient's informed consent
Exclusion criteria
Exclusion criteria: Using SGLT2 inhibitors before starting participation in the study New York Heart Association function class IV heart failure Renal dysfunction (eGFR 3 times higher than upper limit of normal) Body mass index < 18.5 kg/m2 Pregnancy or lactation Patients with the following events within 3 months before the eligibility test: alteration of the anti-arrhythmic drug, catheter ablation for supraventricular arrhythmia, coronary revascularization, open-heart surgery, development of coronary artery disease, stroke or transient ischemic stroke, seizure, infection requiring hospitalization Other commodities, including various infections, major surgery, type 1 diabetes, pituitary or adrenal insufficiency, cancer Single chamber ICDs or ICDs unable to record atrial arrhythmias
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Frequency of the supraventricular arrhythmias (atrial fibrillation and flutter). Timepoint: During the three months before the intervention and during the three months after the intervention. Method of measurement: ICD (implantable cardioverter-defibrillator) record. | — |
Secondary
| Measure | Time frame |
|---|---|
| Fasting blood sugar. Timepoint: At baseline and three months after intervention. Method of measurement: Fasting blood sugar level in blood test.;Blood pressure. Timepoint: At baseline and three months after intervention. Method of measurement: Sphygmomanometer.;Total cholesterol. Timepoint: At baseline and three months after intervention. Method of measurement: Total cholesterol level in blood test.;Heart rate. Timepoint: At baseline and three months after intervention. Method of measurement: Pulse oximeter.;Oxygen saturation. Timepoint: At baseline and three months after intervention. Method of measurement: Pulse oximeter.;Hemoglobin A1c (HbA1c). Timepoint: At baseline and three months after intervention. Method of measurement: Hemoglobin A1c percentage in blood test.;Low-density lipoprotein (LDL). Timepoint: At baseline and three months after intervention. Method of measurement: Level of low-density lipoprotein in blood test.;High-density lipoprotein (HDL). Timepoint: At baseline and three months after intervention. Method of measurement: Level of high-density lipoprotein in blood test.;Triglyceride. Timepoint: At baseline and three months after intervention. Method of measurement: Level of triglyceride in blood test. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMajid Shohrati
Bagheiat-allah University of Medical Sciences
Outcome results
None listed